Sensitivity to DNA damage may act as an early trigger of pulmonary arterial hypertension (PAH), according to researchers at the Universitaire de Cardiologie et de Pneumologie de Québec, in Canada. In the study “DNA Damage and Pulmonary Hypertension,” published in the International Journal of Molecular Sciences,…
News
The Pulmonary Hypertension Association (PHA) International PH Conference and Scientific Sessions in Dallas, Texas broke an attendance record for the organization’s 25-year history of events for awareness, scientific advancement and strong community connection. Patients, families, caregivers, medical professionals, advocates and others —including celebrities Terrence J and Chloe Temtchine – were among…
The Pulmonary Hypertension Association (PHA) was awarded during its 12th International Conference and Scientific Sessions, in Dallas, two new grants to support its work in pulmonary hypertension (PH). To mark the organization’s 25th anniversary also, PHA also awarded several individuals for advocacy, awareness, volunteerism and fundraising service, at the June 17 –…
The European Medicines Agency (EMA), the European Union parallel to the U.S. Food and Drug Administration (FDA), advised that the therapy Adempas (riociguat) should not be prescribed to patients with PH associated with idiopathic interstitial pneumonia (PH-IIP). According to a press release, EMA’s recommendation was supported by results of a Phase 2…
A drug approved for a genetic condition called urea cycle disorder — sodium 4-phenylbutyric acid (4-PBA) — shows a protective effect for pulmonary arterial hypertension (PAH) by decreasing pulmonary artery pressure and mean right ventricular pressure in a PAH rat model. The study, “4-Phenylbutyric Acid Induces Protection against Pulmonary Arterial Hypertension in…
Reata Pharmaceuticals has reported positive interim results from the extension Phase 2 LARIAT clinical trial assessing bardoxolone methyl for the treatment of pulmonary arterial hypertension (PAH). The LARIAT trial is assessing the efficacy, safety, and tolerability of bardoxolone methyl compared to a placebo in patients with PAH. The study aims to determine the recommended…
Researchers from the U.S., Germany, Switzerland, and the U.K. have developed a new questionnaire, to help assess symptoms of pulmonary arterial hypertension (PAH) and the disease’s impact on patients’ lives. The questionnaire, called PAH-SYMPACT, was created following guidance from the U.S. Food and Drug Administration (FDA) to include patient reported outcomes…
Scientists discovered that levels of a blood protein called hematoma derived growth factor (HDGF) increases as pulmonary arterial hypertension (PAH) becomes more severe, which now raises belief that a noninvasive test for the protein could shorten the path to PAH diagnosis and allow treatment at earlier disease stages. The discovery by …
Recently published data from the CHEST-2 clinical trial showed that riociguat (Adempas) is both safe and effective as a longer term treatment of chronic thromboembolic pulmonary hypertension (CTEPH). The study also identified two predictive biomarkers distinguishing CTEPH and pulmonary arterial hypertension (PAH), and their concentrations serve as prognostic guides of…
SteadyMed, Ltd., and the Pulmonary Hypertension Association (PHA) recently launched a new campaign, called PHenomenal, offering patients with pulmonary hypertension (PH) and their loved ones a social media outlet through which to share photos and videos that highlight how fascinating and inspirational they are as people. “My patients with PH continually impress me…
Bellerophon Therapeutics, Inc., announced the enrollment of the first patient with pulmonary arterial hypertension (PAH) in its Phase 3 INOvation-1 clinical study, assessing the efficacy and safety of the next-generation INOpulse delivery system. The portable device is designed to continuously administer inhaled nitric oxide (iNO) to ambulatory patients using a carefully controlled,…
Actelion recently announced that its oral drug Uptravi (selexipag) is now commercially available in Germany for the treatment of pulmonary arterial hypertension (PAH). “The availability of Uptravi is a milestone for PAH patients in Germany, where until now, the options for treatments targeting the prostacyclin pathway have been limited, and were burdensome…
